

Mirati Therapeutics, Inc.  
Form 4  
April 01, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BAKER BROS. ADVISORS LP**

(Last) (First) (Middle)

**667 MADISON AVENUE, 21ST FLOOR**

(Street)

**NEW YORK, NY 10065**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**Mirati Therapeutics, Inc. [MRTX]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**03/30/2016**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common Stock					170,714	I		See Footnotes (1) (7) (8)		
Common Stock	03/30/2016		X		137 <sup>(4)</sup>	A	\$ 6.74	137	D <sup>(2)</sup>	
Common Stock	03/30/2016		X		137 <sup>(4)</sup>	A	\$ 6.74	137	D <sup>(3)</sup>	
Common Stock	03/30/2016		X		310,003 <sup>(4)</sup>	A	\$ 6.74	3,054,055	I	See Footnotes (5) (7) (8)
	03/30/2016		X		3,479 <sup>(4)</sup>	A		43,787	I	

Edgar Filing: Mirati Therapeutics, Inc. - Form 4

Common Stock	\$ 6.74	See Footnotes <u>(6)</u> <u>(7)</u> <u>(8)</u>
--------------	------------	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable      Expiration Date	Title      Amount Number Shares
Common Stock Warrants (right to buy)	\$ 6.74	03/30/2016		X	137 <sup>(4)</sup>	04/04/2011      04/04/2016	Common Stock      137
Common Stock Warrants (right to buy)	\$ 6.74	03/30/2016		X	137 <sup>(4)</sup>	04/04/2011      04/04/2016	Common Stock      137
Common Stock Warrants (right to buy)	\$ 6.74	03/30/2016		X	310,003 <sup>(4)</sup>	04/04/2011      04/04/2016	Common Stock      310,003
Common Stock Warrants (right to buy)	\$ 6.74	03/30/2016		X	3,479 <sup>(4)</sup>	04/04/2011      04/04/2016	Common Stock      3,479

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director    10% Owner    Officer    Other

BAKER BROS. ADVISORS LP  
667 MADISON AVENUE, 21ST FLOOR X  
NEW YORK, NY 10065

BAKER FELIX  
667 MADISON AVENUE, 21ST FLOOR X  
NEW YORK, NY 10065

BAKER JULIAN  
667 MADISON AVENUE, 21ST FLOOR X  
NEW YORK, NY 10065

Baker Bros. Advisors (GP) LLC  
667 MADISION AVENUE, 21ST FLOOR X  
NEW YORK, NY New York

## Signatures

Baker Bros. Advisors LP: Name: Scott L. Lessing Title: President /s/ Scott L. Lessing	04/01/2016
__Signature of Reporting Person	Date
/s/ Felix J. Baker	04/01/2016
__Signature of Reporting Person	Date
/s/ Julian C. Baker	04/01/2016
__Signature of Reporting Person	Date
Baker Bros. Advisors (GP) LLC :Name: Scott L. Lessing Title: President /s/ Scott L. Lessing	04/01/2016
__Signature of Reporting Person	Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in 170,714 shares of Common Stock of Mirati Therapeutics, Inc. (the "Issuer") directly held by 667, L.P.

- (1) ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.  
  
Represents common stock of the Issuer held directly by Julian C. Baker. The common stock was received from the exercise of warrants to
- (2) purchase common stock of the Issuer which was received in an in kind pro rata distribution from an affiliated investment fund in September 2015 without consideration.  
  
Represents common stock of the Issuer held directly by Felix J. Baker. The common stock was received from the exercise of warrants to
- (3) purchase common stock of the Issuer which was received in an in kind pro rata distribution from an affiliated investment fund in September 2015 without consideration.
- (4) Represents the exercise of warrants for common stock of the Issuer at an exercise price of \$6.74 per share.  
  
After giving effect to the transaction reported herein, and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common
- (5) Stock reported in column 5 of Table I directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
- (6) After giving effect to the transaction reported herein, and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 14159, L.P. ("14159" and together with Life Sciences and 667, the "Funds"), a limited partnership of

## Edgar Filing: Mirati Therapeutics, Inc. - Form 4

which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

(7) Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

(8) Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.